Webinars & Videos

A recap of new GLP-1 research to help you make sense of the new information seeming to hit the news (and your inbox) almost daily

Experts weigh in on the results of a new survey on GLP-1 trends from 300 PCPs, endocrinologists and obesity-certified specialists.

With new anti-obesity meds in the pipeline, including oral GLP-1s, and healthcare costs rising exponentially—what happens next?

A first of its kind research study from Virta Health shows sustained weight loss after deprescribing GLP-1s among a real world population.

Not all lifestyle change programs are created equal. Learn why most diet and exercise programs fail and how you can help your members succeed with sustainable lifestyle change.

Get the results of a new survey of 60 senior health plan leaders to understand how the GLP-1 cost crisis is evolving and how they are handling it.

Whether your organization has felt the tidal wave of GLP-1 claims yet or not - it's coming. Learn about a new set of options to navigate this spike.

GLP-1 drugs are hitting the market with new indications but are rising utilization and prices widening health disparities?

Find out why leading orgs, like AutoZone, are putting a bullseye on underperforming management programs and upgrading to reversal.

Digital healthcare has long touted a promise to address health disparities, but is the new wave of solutions making any headway in closing health equity gaps in type 2 diabetes? Research says yes.

More than 150 million Americans depend on employer-sponsored insurance (ESI) for their health care, but the health outcomes of ESI enrollees has not been well understood given historical data gaps and limitations in analyzing health outcomes across race, ethnicity and income.

AutoZone Vice President, Matt Harmon, talks about partnering with Virta to reverse prediabetes, obesity and type 2 diabetes for his employees.